NCT02059460View on ClinicalTrials.gov

Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney

PHASE4CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 31, 2013

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Acute Kidney InjuryLiver TransplantationTerlipressinNGAL
Interventions
DRUG

Terlipressin

Terlipressin (Glypressin®) will be started by continuous infusion at a dose of 1-4 µg/kg/h till day 4 postoperatively

DRUG

placebo

Trial Locations (1)

32511

National Liver Institute, Shebeen Alkom

All Listed Sponsors
collaborator

Dr. Mohamed Helmi Ibrahim Afifi

UNKNOWN

collaborator

Dr. Khaled Ahmed Yassen

UNKNOWN

collaborator

Dr. Khalid Mousa Abouelenain

UNKNOWN

collaborator

Dr. Mohamed Abdelrauf kandil

UNKNOWN

collaborator

Dr. Ayman Alsebaey Qotb Alghoraieb.

UNKNOWN

lead

National Liver Institute, Egypt

OTHER

NCT02059460 - Perioperative Evaluation of Terlipressin Infusion During Living Donor Liver Transplantation on Incidence of Acute Kidney | Biotech Hunter | Biotech Hunter